Replies to post #130405 on Innovation Pharmaceuticals Inc (IPIX)

[biodoc]

NP, rule. I know there was other important dialogue but the dosing calculations were part of my first post last august:

conversion of IP animal dosing to human dosing

My thinking is a little different now but it seems likely that the last two cohorts delivered higher peak concentrations of kevetrin though the IP model may have allowed for longer duration of kevetrin exposure. Also, I have no idea if the IV infusion over several hours makes the IV and IP peaks somewhat comparable.

I still think kevetrin could yield maximum effect with the fewest side effects by titrated continuous infusion. Eliminate peaks/troughs, establish steady state. So many of these patients already have indwelling IV access ports and the newer delivery pumps are really nice.